MCL Literature Feed
147 papers on mantle cell lymphoma from PubMed. Updated daily.
A rare case of primary adrenal mantle cell lymphoma presenting as a retroperitoneal mass mimicking paraganglioma highlights the critical need for histological diagnosis of atypical adrenal tumors.
A case of primary ocular adnexal MCL demonstrates its potential for rapid systemic progression, emphasizing the need for thorough initial staging and aggressive systemic therapy despite localized presentation.
This retrospective study confirms that progression of disease within 24 months (POD24) after initial therapy is a strong negative prognostic marker for overall survival in MCL patients.
This case report describes a rare presentation of primary MCL causing life-threatening laryngotracheal stenosis, highlighting the need to consider lymphoma in the differential diagnosis of acute airway obstruction.
In young, newly diagnosed MCL, first-line rituximab, bendamustine, and cytarabine (R-BAP) plus a BTK inhibitor improved complete response and PFS over standard R-CHOP/R-DHAP in a real-world setting.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
In young, newly diagnosed MCL patients, adding ibrutinib to chemoimmunotherapy improves failure-free survival, establishing a new standard and questioning the necessity of autologous stem cell transplant consolidation.
The phase 3 TRIANGLE trial established that adding ibrutinib to induction/maintenance allows omission of autologous transplant in young, fit MCL patients, providing a new frontline, transplant-free standard.
This review summarizes the clinical data and rationale for targeted agents like BTK and BCL2 inhibitors, highlighting the paradigm shift away from chemotherapy in both relapsed/refractory and frontline MCL.
This case links progressive necrotizing xanthogranuloma, a rare paraneoplastic syndrome, as the presenting sign of MCL, underscoring the need for hematologic workup for specific skin/ocular findings.
Real-world registry data from Ukraine (2019-2021) reports a 3-year overall survival of 61% for newly diagnosed MCL patients, providing a crucial benchmark for outcomes in this region.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This case report describes a rare presentation of primary, localized orbital mantle cell lymphoma successfully managed with local excision and radiotherapy, highlighting an unusual clinical scenario for this systemic disease.
A transplant-sparing frontline regimen of lenalidomide-R-CHOP/R-HiDAC showed favorable outcomes in TP53 wild-type high-risk MCL, but not TP53-mutated MCL, reinforcing the prognostic power of sequential MRD monitoring.
This retrospective analysis shows peripheral blood Ig-HTS MRD testing (clonoSEQ) effectively predicts relapse earlier than imaging in MCL patients, supporting its use as a surveillance tool post-frontline therapy.
This case report describes the rare Warburg effect (severe hypoglycemia, lactic acidosis) in an MCL patient, highlighting its potential for cardiac toxicity and the utility of hemodialysis for stabilization.
Real-world UK data show first-line ibrutinib is effective and tolerable for older MCL patients, but high-risk subgroups (TP53-mutated, blastoid) have significantly inferior survival, highlighting an unmet need.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
Long-term follow-up confirms rituximab maintenance post-transplant significantly improves overall survival in young, fit MCL patients, establishing this as a standard of care in the frontline setting.
Palliative radiotherapy provided profound tumor reduction for an elderly patient with blastoid MCL presenting as a rare oropharyngeal mass, demonstrating a personalized, less-intensive frontline treatment option.
In elderly MCL, rituximab maintenance benefits even MRD-negative patients post-induction, arguing against de-escalation and identifying MRD-positivity as a high-risk feature needing better consolidation.
This case report demonstrates that filgrastim-induced HLH in an MCL patient can be managed by switching to lenograstim with steroid prophylaxis, allowing continuation of intensive chemotherapy.
Optical genomic mapping (OGM) identifies rare CCND1 rearrangements, securing an MCL diagnosis in atypical CD5-negative, non-nodal cases that mimic other indolent B-cell lymphomas.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This case report documents the first complete response of frontline CNS-involved MCL to single-agent acalabrutinib, suggesting a potential chemotherapy-free, CNS-penetrant option for this high-risk population.
The British Society for Haematology provides updated, evidence-based guidelines on MCL diagnosis, risk stratification, and treatment algorithms, standardizing care for UK patients.
Combining the MCL35 gene signature with s-MIPI and blastoid cytology powerfully risk-stratifies older, frontline MCL patients receiving bendamustine-rituximab, identifying a dismal prognosis subgroup.
A rare case of extranodal composite MCL and classical Hodgkin lymphoma highlights the need for comprehensive pathological workup to identify dual pathologies, which impacts treatment and relapse patterns.
This case of asymptomatic multiple lymphomatous polyposis in an elderly MCL patient demonstrates that significant GI involvement can be clinically silent, reinforcing the need for routine endoscopic staging.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This case report details an extremely rare MCL presentation of bilateral hemorrhagic hypopyon, successfully treated with intravitreal rituximab, systemic chemotherapy, and radiation, expanding the differential for unusual ocular findings.
This phase 1 study established the safety and preliminary efficacy of a novel bortezomib, cladribine, and rituximab regimen for older, newly diagnosed mantle cell lymphoma patients.